Table 2.
Baseline characteristics of CKD in patients developing AKI
| CKD cause, n (%) | |
| Nephroangiosclerosis | 85 (37.61) |
| Diabetic nephropathy | 45 (19.91) |
| Chronic tubulointerstitial nephropathy | 24 (10.62) |
| Glomerulopathy | 15 (6.64) |
| Solitary kidney | 14 (6.19) |
| Cardiorenal syndrome | 11 (4.87) |
| Vascular | 7 (3.10) |
| Other (multiple myeloma, polycystic disease) | 2 (0.88) |
| Unknown | 23 (10.18) |
| Dipstick proteinuriaa (mg/dL), n/n (%) | |
| <30 | 114/162 (70.37) |
| 30–100 | 36/162 (22.22) |
| 100–300 | 8/162 (4.94) |
| 300–1000 | 4/162 (2.47) |
| Microhaematuriaa (>10 RBC/hpf), n/n (%) | 23/160 (14.38) |
| Albuminuriaa (mg/g), median (IQR) | 37.44 (30.01–227.94) |
| Ureaa (mg/dL), mean (SD) | 69.31 (25.32) |
| sCrb (mg/dL), mean (SD) | 1.40 (0.41) |
| Estimated filtration rate CKD-EPIb (mL/min/1.73 m2), mean (SD) | 46.63 (13.24) |
a
Last available control from nephrology department or primary care registries up to 1 year before COVID-19 hospitalization.
b
Highest values registered from nephrology department or primary care up to 1 year before COVID-19 hospitalization.
RBC/hpf, red blood cells per high power field.